Achievements in science, tech advancements, shifts in health policy, a renewed interest in preventative care, and tackling health disparities can shift how we improve people’s health. Will these topics be front and center at HLTH?  We’ll know more in the days ahead. 

10 Predictions for the HLTH Main Stage

Here are my 10 predictions for health innovation in 2024 that have the potential to transform health – topics that should be woven into the commentary during HLTH mainstage conversations – that can make the most significant impact to improve people’s outcomes, reduce costs, and advance wellness. Let’s see what next weeks social media posts provide that give us indication of the changes ahead.

Prediction 1: AI-Driven Medicine Saves Lives

ChatGPT and AI (augmented intelligence) made their big public splash this year!  However, Microsoft and evangelists such as Tom Lawry and John Nosta have been pointing to AI as a life-sustaining tool in health for years. Surprisingly, “big data and “machine learning didn’t attract the same attention as the newest label – AI!  These technologies enable the development of highly personalized treatment plans based on an individual’s genetic makeup, medical history, and lifestyle and risk factors. AI-driven predictive models will assist health providers in making more accurate diagnoses faster and tailoring treatments for optimal patient outcomes.

Prediction 2: Telemedicine and Virtual Patient Monitoring Go Mainstream

Telemedicine saw unprecedented and “no alternative” growth during the COVID-19 pandemic.  It should continue to see prominence in 2024. Improvements in telehealth infrastructure and regulatory support make virtual consultations with health professionals accessible and efficient. One challenge has been reimbursement for providers compared to in-office visits.  There is a time and place for in-person care and virtual engagement.  Regardless, the urgencies of people in rural and remote communities and preventive care needs make telemedicine and virtual patient monitoring public health priorities.  There is no going back!

Prediction 3: Women’s Health Innovation Prioritized

Women’s health remains under-researched and is barely prioritized by biopharma companies and government-supported research grants. Women comprise half the adult population, but research into women’s health needs is embarrassingly low. The National Institutes of Health directs $42 billion on medical research annually, but only $5 billion of those funds are targeted to women’s health priorities. One global company stands out as a leader – more are needed. In the 1990s, women were more likely to die from their first heart attack compared to men due to gender bias. While those statistics have improved, women still face numerous public policy and care disparities – among the more pressing challenges – reproductive choice. These issues should take center stage and HLTH may be the platform for this long over-due (and urgent) conversation.

Prediction 4: Digital Therapeutics Take Center Stage

Digital therapeutics, including smartphone apps and wearables, will become integral to health intervention and connection. These innovative tools help patients manage chronic conditions, monitor vital signs, and adhere to treatment plans. The gamification of health through digital therapeutics will encourage patient engagement and long-term health outcomes.  Sector leaders, like Click Therapeutics Founder David Klein, are adopting “biopharma” like research models to demonstrate their value to patient care by conducting well-designed clinical trials that show complementary benefits with and with other therapies.  Those enterprises will set the stage for the future of digital therapeutics and redefine the category.

Prediction 5: Health Data Privacy and Security

Despite the hype, consumer-friendly cybersecurity technologies can shift how health data is managed and shared. Patients will have greater control over their health information and records, with the ability to securely share them with health providers, clinical researchers and other stakeholders as needed. Data that cannot be accessed or shared transparency and securely is useless in sustaining and saving lives. Consumers and health professionals need easier ways to protect sensitive health information and streamline data exchange for improved care coordination. EMRs are great if they offer convenient use and application; however, they are too often a jumble of inaccessible information. Security and utility are key! So long (hopefully) fax machine!

Prediction 6: Obesity as a Treatable Disease

Among the most dramatic ways to reduce disease burden and address heart disease, diabetes, respiratory illness, and even some cancers is to take obesity (very) seriously.  It Is not only about weight reduction but understanding that obesity is a domino effect, a multi-system disease. Weill Cornell’s Louis J. Aronne, MD‘s pioneering work recognized early that seeing this only as a “weight problem” underestimates its enormous human health impact. More and more, physicians will need to tap into the expertise of specialists to guide their treatment decisions.  With new medications available, physicians will examine the problem and think about solutions.  However, reducing weight is only part of the clinical response.  Getting it right will save millions of lives and billions in costs.

Prediction 7: Robotics and Automation

Don’t be surprised when robotic technology is increasingly integrated into health systems ORs and patient-care wings. Robots will soon perform set surgical procedures, dispensing medication, and performing patient-care tasks. Watch for Rafael Grossmann, MD, who first used Google Glasses in the OR to push the boundaries on what is possible and needed.  Automation will enhance efficiency, reduce human error, and improve patient safety. Robotic exoskeletons will also aid in rehabilitation and mobility for individuals with physical impairments. But remember the human touch!  While ChatGPT has become a patient favorite in searching out information and robotics will transform the patient experience, people’s confidence in skilled medical professionals remains paramount.

Prediction 8: Mental Health Priorities

There is a long-needed shift toward destigmatizing mental health issues and increasing access to mental health services. AI-powered chatbots and virtual therapists will provide on-demand support, while data analytics can identify at-risk individuals and tailor interventions. Virtual reality therapies will increasingly become a mainstream treatment option for anxiety and PTSD.  Services and upskilling are becoming an investment and professional-development priority.  However, while tech has a place in the process, there is something to be said for developing a personal relationship with a licensed psychologist or licensed clinical social worker skilled in face-to-face therapy. It’s always about caring for people!

Prediction 9: Global Collaboration for the Next Pandemic

The COVID-19 pandemic highlighted the importance of global collaboration in addressing public health emergencies. In 2024, international cooperation and data sharing must be at the forefront of pandemic preparedness. A global surveillance network will provide early warning systems, and rapid vaccine development platforms should be established to respond to emerging infectious diseases quickly.  COVID was a test run, and from a public health information standpoint, the developed nations stumbled.  From disappointment comes learning. Collaboration among public health professionals, policymakers, and medical innovators was paramount to the – even stymied – response. 

Prediction 10: Ethical Considerations for Health Innovation

As health innovation advances in 2024, ethical considerations must take prominence. The long overdue pain revealed during COVID must shift mindsets, behaviors and budgets. We must expect increased scrutiny and priority around data privacy, AI bias, health, and attention to racial and gender disparities.  We must set a path for responsible use of emerging technologies. We must recognize that public policy cannot diminish people’s care options. Ethical frameworks and regulations will be developed to ensure that health innovation benefits all people – and all nations – while respecting access, rights, and values.

A Common Call to Action at HLTH

These 10 predictions are a glimpse into the possibilities of what we might hear from speakers during HLTH. AI-driven personalized medicine, telemedicine and virtual patient monitoring, women’s health, digital therapeutics, cybersecurity, obesity management, robotics, mental health innovation, global collaboration, and ethical considerations should be front and center in the conversation to improve people’s health and well-being.  Life is often referred to “as a game.” It’s not. Health access cannot be roulette wheel spin left to chance. It requires advocacy, policy, planning and empathy. Kindness is a human quality that must be given center stage.

Right now, the people who often need preventive and primary care services face the most significant hurdles.  These predictions are based on one underlying principle – health innovation can only achieve its greatest potential when available to those with the greatest needs.  Hopefully, we’ll hear from more and more speakers stepping to the stages at HLTH that shared call to action.

The post When It Comes to the Future of HLTH – Life Is Not a Las Vegas Roulette Wheel appeared first on Medika Life.

The digital health sector has grown significantly during the past decade, primarily mobilized to address unmet health-system and care needs. From $2 billion invested in 2011, that figure morphed 28-fold to $56 billion in 2021. In the shadow of the COVID pandemic, unprecedented investment poured into digital health during this two-year window, accelerating the adoption of AI, remote patient monitoring, telehealth, digital therapeutics, wearables, VR and more.

DOWNLOAD THE FULL REPORT HERE

Galen Growth and FINN Partners have collaborated – for a second time – to offer the entrepreneurial invention and investment industry a wealth of data that can guide financing life-sustain – perhaps saving – enterprises.  With this detailed report, data is shared not as “one-off” ideas but as puzzle pieces assembled to provide actional insight into a dynamic and evolving digital innovation sector that offers the transformative power to find effective detours around health ecosystem fragmentation.

The Damocles Sword of Access and Outcomes

The two companies avoided hype and biases to create this analysis enabling investors or potential business partners to weigh subjective decisions alongside objective facts in recognizing that the fragmented health ecosystem centers around preserving the system itself are vital to helping product innovators and patients navigate the healthcare labyrinth. That economic return on investment is weighted along with patient experience and outcomes.  This is the Damocles sword that inventors and investors must always consider – reimbursement that ensures access to care and meaningful and measurable outcomes.

While digital health venture capital fell short of the exorbitant funding of 2021, it closed ahead of 2020 levels. A closer look at the year-on-year development of funding value by funding stages shows that funding in 2022 nearly maintained the level of 2021 for the Early Stage and Series A funding rounds. However, it lagged behind the 2021 values across late-stage enterprise funding.

Investors learned and began to put their due diligence into action – targeting their energies toward specific geographies, sectors and needs (e.g., clinical trials).  They looked for therapeutic categories receptive to digital health innovation.  Within the disease-specific investments, oncology saw the highest participation of investors (9%), followed by mental health (7%) and women’s health (7%).  C-Suite leaders and their funders will do well to study the report data and to determine next steps.

Just Facts – 250+ Million Data Points Analyzed

While other studies highlight “media grabbers” and numbers disconnected from insight into where the money is going — from the investment stage to disease states— The Global State of Digital Health connected more than 250 million critical analytic dots. This report will guide C-Suite leaders, business development and therapeutic area heads, private equity funds, and financial analysts to make savvy decisions that drive return on investment—whether the goals be financial or patient care.

After an extraordinary two-year pandemic funding spree, there are apparent shifts in how investors place their economic bets. In this year of geopolitical turmoil and uncertain financial performance, digital health remains vital to the future of the health economy and in addressing public health press points. However, the development stages in which funds are directed, therapeutic categories selected, provider systems that demand transformation, and the regions where innovators establish headquarters are now investment factors.

Bottomline, funding levels exceed the pre-pandemic values. Digital health ventures are busy – submitting more than double the number of regulatory filings in 2021 than before the COVID era. There is a dramatic increase in partnering activity over 2021. If dollars and Euros are the only indicators of energy and commitment, it is easy to see why hand-wringing news stories prevail. Look at all the metrics that determine a vibrant sector.

In combining investment, regulatory filings for new product introductions, and partnerships, it is apparent that 2022 has been a formative period. Investors and innovators are putting in place the processes and systems – the people and science – that drive adoption and market traction. Investors are no longer looking at the sector as monolithic.

Putting the Right People and Processes on the Innovation Bus

If 2021 was the year of exuberance, 2022 was, as Jim Collins, author of the classic business bestseller “Good to Great,” dedicated to putting the right people – leaders and digital health sectors – on the bus. For example, medical diagnostics ventures had an exceptional year by representing 12 percent of regulatory filings of Digital Health ventures across the globe, taking the top spot for ventures with significant Clinical Evidence (Evidence Signal >40), and capturing the highest investment volume share (17%), with the total cluster funding value falling short of 2021 by 16 percent.

As the report suggests, 2022 is a turning point for digital health – a shift from Digital Health 1.0 to the 2.0 era, with Digital Health evolving into a more mature ecosystem. The recent data reaffirm that perspective and a fast-paced realignment occurring within the sector.

Looking at the past year, it is evident that investor mindsets matured in 2022, and lessons learned were applied. Obstacles – from regulatory hurdles to payer pushback – made incubators, accelerators and private equity groups much more selective in their investment and partnership decisions. They looked beyond “invention” to innovation – where the market seeks to embrace a new product and rally to Foreword its access within the health ecosystem.

The 2022 “Global State of Digital Health Report” does far more than examine monies invested in the broad digital health category — it offers a guide for decision-makers on how multiple data points translate into market shifts and how to pinpoint trends that provide predictive insight and best practices in investment strategies, across regions, Digital Health categories, therapeutic areas and technologies.

Decisions will be made based on this collaborative effort. This report offers a new perspective – the data this report provides – finding the balance between hype and hope to offer balanced optimism is a guide.

The post Digital Health Innovation Continues to Press Forward at Warp Speed appeared first on Medika Life.

With only a few children having received their covid vaccines, there are enough numbers among the under 16’s to push us over the finish line, so to speak. The obvious question now is how do parents feel about the Covid vaccine and their children? Will they encourage them to be vaccinated?

A new nationwide survey released today from the COVID Collaborative, Ad Council, and the Council of the Great City Schools shows that 61% of parents plan to vaccinate all of their children, but 27% are against vaccination and 12% remain mixed or undecided.

How is this view affected by racial and ethnic groups across the country? Asian American and Pacific Islander parents are the most likely to vaccinate their children (77%) and Black parents are the least likely (55%). The age of the children also impacts vaccination adoption. While at least 65% of parents of children ages six to 17 plan to vaccinate their children, only 56% of parents of children under the age of six will vaccinate their children.

The study was commissioned by COVID Collaborative, a project of UNITE, a national assembly of experts, leaders, and institutions in health, education, and the economy and associations representing the diversity of the country to turn the tide on the pandemic by supporting federal, state and local COVID-19 response efforts.

Other key takeaways from the new study revealed the following attitudes among US parents towards child vaccinations.

• Most parents have heard something about new variants and severe illness from COVID-19 in children, but there is room to increase understanding.
• Vaccines will play an important role in making parents feel safer sending their children to school. More than seven in 10 parents with children in school would feel safer sending their children to school if their children were vaccinated or if they knew that most other students were vaccinated.
• There is widespread support for making vaccines and information about them available at public schools, and nearly three in five parents of children in school support requiring students to get vaccinated to attend school in person.

The survey also revealed very interesting data on who parents trust to inform them about vaccines and vaccine safety.

Parents least likely to say they will get their children vaccinated against COVID-19 include those who live in small towns and rural areas (42% will get all children vaccinated), those aged 18 to 29 (46%), women 18 to 39 (51%), White mothers (51%), Black mothers (45%), women without a college education (47%), Independents (48%), and Republicans (53%); and most of these groups are among those least likely to say they have been or will get vaccinated themselves.

“Parents want to keep their children safe and in school,” said John Bridgeland, CEO of COVID Collaborative. “This survey provides important insights to increase parent confidence in vaccination, which will enable children to be safe for in-person learning, on playgrounds, and for other activities that help them grow and thrive.”

Just exactly who was polled in the survey? COVID Collaborative also provides a detailed breadown.

The research for this study was conducted by Hart Research for theCOVID Collaborative, a national assembly of experts across health, education, and the economy working to support local, state, tribal, and federal leaders in turning the tide against the pandemic. The study contains many more fascinating facts and figures and you can access the whole report here.

The post New Survey Reveals 6 in 10 Parents in Favor of Covid Vaccine for Their Child appeared first on Medika Life.

Some excellent, large data sets were either being put to purposes which they weren’t well suited or authors were drawing conclusions that really weren’t the results of analyzing the data.

Why can’t they just report their results accurately and transparently and not be afraid of doing so?

Journals are a big part of the problem. They seduce researchers with temptations that they cannot resist.

A while ago the JAMA family of papers spent millions of dollars revamping their publishing platform. The publisher announced that editors were going to make decisions about papers based on altmetrics — how much traffic similar papers have attracted to the journal website, and how much time readers spent there, and therefore how much the journal could charge for advertising.

That means that some papers that are solid science and have important messages for mental health care will be given lower priority. The papers are not in hot, trending topic areas and would not attract broader audiences.

Despite being obviously weak in their methods or data, other papers will be accepted because they are trendy in their conclusions. Some papers will be rejected because they persuasively present inconvenient findings.

In the case of this issue of JAMA Psychiatry, an obvious decision was made by the editors to emphasize racial and ethnic health disparities in a special section Psychiatry and COVID.

A call went out for papers. I doubt that some of the authors even had that intention of examining health disparities or racism in mind when they gathered their data and made plans to analyze it.

I am picking one article to dissect because I have a great deal of respect for one of the authors. I’ve followed his work closely for decades because he does very good work. I think he knew what he and his co-authors were doing in putting a message on their results that weren’t there. He was having harmless fun and not trying to corrupt science.

Naively or on purpose, Greg Simon allowed his co-authors to say silly things in the section discussing implications, where such speculations seem natural.

Maybe I am giving too much credit to Greg but what I liked was that this paper was so transparent in how he manipulated the reviewers and the readers. Right away, he revealed what he was up to in an incredibly transparent abstract. Like a magician spoiling the trick by explaining what he was doing, he was communicating to the smart, attentive members of the audience and allowing them to feel smart. Too bad that most people do not read carefully.

The article could be paywalled by now, but you can access the abstract here and see the context of the statements that I am going to pick out.

The authors state as their research question:

*Could implementation of suicide prediction models reinforce and worsen racial/ethnic disparities in care?”

Translation: How white people’s science hurts black and indigenous people and perpetuates systemic racism.

The huge retrospective study consists of administrative data of 13,980,570 visits by 1,433,543 patients. The data came from seven health systems providing integrated physical and mental health services.

The authors used sophisticated statistics to construct a model predicting which patients would die by suicide within 90 days of when observation of a particular patient started.

The authors conclude

These suicide prediction models may provide fewer benefits and more potential harms to American Indian/Alaskan Native or Black patients…Improving predictive performance in disadvantaged populations should be prioritized to improve, rather than exacerbate, health disparities.

Unraveling this conclusion

In epidemiological/mental health services studies, it is not how big your data set is that matters, but how many events you are available for particular groups.

From the clearly written and transparent abstract, you can tell right off that the data set is not very good to be used to predict black and Native American suicides because there were so few Blacks and Native Americans in the sample.

Hiding in plain sight in the abstract, the authors openly admitted that they only had n=65 black who died by suicide within 90 days of when tracking starred. They only had n= 21 Native Americans who died by suicide within 90 days of when tracking starred.

These are horribly small numbers, even useless, to be used in making generalizable scientific statements. But the situation is even worse. The sample was split between building and validating the model. In the validating sample, there were only 30 black patients and 15 Native Americans.

The authors claim that their predictive model worked well for whites. That would be expected without even seeing the predictive model, because it was built to a predominately white sample.

But who should care about this predictive model?

Recall this was an administrative data set constructed from information collected for other purposes. The diagnosis and service utilization data in the final predictive equation are so crude that the model would not be clinically useful in real-world settings. Maybe it delights epidemiologists for looking so good in terms of statistical significance, but clinicians should ignore it. I am sure that they will.

Every suicide is a tragedy, but because it is such an infrequent event, a base rate “won’t die by suicide” is likely to be more accurate than a predictive model based on group data. Aficionados will recognize that is a classic Paul Meehl observation.

Here comes the pablum.

Pablum is boring tasting baby food. Authors put pablum in papers because they need a filler.

Readers expect certain things to be said about a trending topic, even if things were not among the findings of the paper. Alert reviewers play gatekeeper and keep pablum out of the discussion section if they are not actual findings. In this paper, the authors make the unsubstantiated claim:

Relative benefits and harms of suicide prevention interventions vary by race/ethnicity. Additional attention from a mental health care professional may increase access to beneficial services and likely presents limited harm but could cause stigmatization or discrimination and damage patient-practitioner therapeutic alliances, particularly for patients from marginalized communities already less likely to trust or engage with traditional mental health care.

This may be true or not in other findings that were not cited. Why are the authors bringing this up near the end of a paper that was doomed from the start not to advance our understanding of suicides by ethnic and minority persons?

Of course, a journalist from MedPage Today fell for the trick and gave the authors some extra publicity. One of the authors of the study is quoted in the MedPage Today article:

“We must not ignore unintended consequences of suicide prediction models,” she said via email. “Identifying patients at high risk of suicide could initiate a cascade of more intrusive interventions, including involuntary psychiatric hospitalization and ‘wellness checks’ that put a patient in contact with law enforcement. We have to recognize, due to structural racism, that the risk of these harms is greater for BIPOC [Black, Indigenous, and people of color] populations.”

A touch of moral panic attracts more readers to MedPage Today and the JAMA Psychiatry article, keeping MedPage Today, JAMA Psychiatry, and the authors’ institution happy.

But science suffers from the confirmation of a hypothesis that was not tested, especially when the paper is cited for this conclusion that did not arise in the data.

What important message about racism and health disparities is missing in this paper?

Unwarranted talk about systemic racism distracts from looking for real, modifiable racial disparities.

Mental health services researchers like these authors require large data sets, which come from settings that are organized enough to provide them. This particular study relied on integrated care settings in which patients could easily access both primary medical and mental health treatment. These settings depend on an alignment of incentives, insurance benefits that make integrated care possible.

There were not many black or Native American suicides for which data were available in the settings. That is a serious health disparity. Such patients don’t get to such settings.

Black or Native Americans don’t have the right insurance or live in close proximity to such quality care. It is a long way from most Native American reservations to the doorsteps of a well-resourced integrative care setting. Those who reside on a reservation mostly won’t have the proper insurance nor the transportation to get there.

That was strongly suggested by taking a peek at what data the authors collected or even where they collected it. Nothing fancy had to be done, but then again, they probably would not get their paper in the prestigious JAMA Psychiatry,

You might think from this article that there is harm and even danger for Native Americans to be treated in one of the settings that were studied.

I have a close native American relative by marriage whose 90+ years old (It has to be a guess because birth certificates of many Native Americans are not preserved from back then.) grandmother was a reservation orphan from another tribe who was sent to a Navajo reservation because that nation was able to keep polio victims in the 50s. I wish she could get all the treatment of post-polio syndrome that she deserves in the reservation. She wants to keep working for the US National Parks Service, as she has for decades, and accessible integrated care would help.

Algorithms that poorly predict individual suicides of any race or ethnic background be damned. If we care about social disparities in health, we must concentrate on getting more blacks and Native Americans into treatment in integrated care settings.

The post Suicidology Is Corrupted by Researchers Who Say Things That Aren’t in Their Data appeared first on Medika Life.

NEW YORK /PRNewswire/ — The “Global Dental Surgical Equipment Market 2020-2024” report has been added to Technavio’s offering.

The dental surgical equipment market is expected to grow by USD 1.42 billion during 2020-2024, expanding at a CAGR of almost 6%.

The report also throws light on the impact of the COVID-19 pandemic on the market and the new opportunities and challenges market players can expect. The impact can be expected to be significant in the first quarter but gradually lessen in subsequent quarters – with a limited impact on the full-year economic growth.

The report offers a detailed analysis of the impact of the COVID-19 pandemic on the market in optimistic, probable, and pessimistic forecast scenarios.

Download Sample Report

Dental Surgical Equipment Market: Increasing Prevalence of Dental Diseases and Related Risk Factors to Drive Growth

This post-pandemic global dental surgical equipment market report has assessed the shift in consumer behaviour and has identified and explored the upcoming trends and drivers that the vendors can capitalize on to support prompt business decisions. Increasing prevalence of dental diseases and related risk factors coupled with growth in the number of dentists and dental practices will offer immense growth opportunities. Moreover, this study identifies favorable reimbursements and tax benefits as one of the key trends for dental surgical equipment market growth during the next few years.

Is there any relief during this COVID pandemic?

Request Free Sample Research Report

As per Technavio, the favorable reimbursements and tax benefits will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other significant trends and market drivers that will influence market growth over 2020-2024.

Related Reports on Health Care Include:

Dental Cone Beam Computed Tomography Market by End-user, Application, and Geography – Forecast and Analysis 2020-2024: The dental cone beam computed tomography market size has the potential to grow by USD 255.14 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period. To get extensive research insights:

Get FREE Sample Report in Minutes!

Dental Surgical Equipment Market: Segmentation Analysis

This market research report segments the dental surgical equipment market by product (Dental systems and equipment and Dental lasers) and geography (North America, Europe, Asia, and ROW).

North America had the largest market share in the dental surgical equipment market in 2020, and the region will offer several growth opportunities to market vendors during the forecast period. The adoption of 3D printing technology will significantly influence biofuels market growth in this region. 38% of the market’s growth will originate from North America during the forecast period. The US is one of the key markets for dental surgical equipment market in the region.

Technavio’s sample reports are free of charge and Gain competitive intelligence about market players. Track key industry trends, opportunities, and threats. Inform your marketing, brand, strategy, and market development. 

Request a free sample report

Some of the key topics covered in the report include:

• Market Challenges
• Market Drivers
• Market Trends
• Vendor Landscape
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Report: https://www.technavio.com/report/dental-surgical-equipment-market-industry-analysis

SOURCE Technavio

Related Links

http://www.technavio.com/

The post Dental Surgical Equipment Market 2020-2024 appeared first on Medika Life.

SAN FRANCISCO /PRNewswire/ — The global telemedicine market size is expected to reach USD 298.9 billion by 2028, according to a new report by Grand View Research. The market is expected to expand at a CAGR of 22.4% from 2021 to 2028. Key drivers of the market include increasing incidences of chronic conditions and rising demand for self-care. Furthermore, enhancing internet application, virtual medicine and rising demand for centralization of healthcare are expected to save on cost incurred, which is one of the critical success factors attributing to market growth.

Key suggestions from the report:

• The product segment registered largest revenue share in 2020 due to increasing adoption of remote monitoring devices
• Increasing demand of automation and synchronization across the system is anticipated to be the key driving factor for the real time technology segment
• Telemedicine found wide applications in dermatology, psychiatry, intensive care units, emergency care, ophthalmology and radiology. The teleradiology segment accounted for the largest revenue share in 2020
• The web/mobile based delivery model is expected to witness significant growth in coming years due to high adoption of smartphones and penetration of internet
• The tele-homecare segment is anticipated to witness a lucrative CAGR in coming years due to increasing awareness pertinent to benefits of remote healthcare amongst patients and introduction of advanced technologies to monitor patient’s health from remote locations
• The patients segment held the largest revenue share in 2020. Government initiated healthcare programs across the world are anticipated to propel segment growth in coming years
• North America dominated the market as there is high adoption of telehealth solution due to COVID-19 pandemic. Availability of advanced healthcare facilities with plenty funds contributed to the emergency care delivery to stop spread of the disease is contributing towards the growth of the market in the region
• In Asia Pacific, the market is predicted to witness lucrative growth over the forecast period. Developing economies such as China and India are facing challenge to provide access to patients due to corona outbreak is expected to boost the adoption of telemedicine services in this region. Economic reforms, boosting IT industry, and low functioning costs are the key factors attracting market players to participate in this region
• Telemedicine products are distributed by direct supply contract amongst the manufacturers and end users or maybe concluded via a third-party supplier

Read 150 page research report with ToC on “Telemedicine Market Size, Share & Trends Analysis Report By Component, By Technology, By Application (Teleradiology, Telepsychiatry), By Delivery Mode, By Type, By End-use, By Region, And Segment Forecasts, 2021 – 2028” at: https://www.grandviewresearch.com/industry-analysis/telemedicine-industry

In the U.S. both state and federal laws have evolved to facilitate the widespread use of telemedicine to cope up with the COVID-19 pandemic. For instance, in March 6, 2020 the U.S. president signed Coronavirus Preparedness and Response Supplemental Appropriations Act. It includes USD 8.0 billion emergency funding for the federal agencies and to expand reimbursement coverage for telehealth services. Various U.S. states also waived of the licensure for better utilization of the service. This positively impacted the market growth during the pandemic.

Rapid advancements in technology is further expected to boost the demand for online consultation, thereby contributing to the market growth of telemedicine solutions and services over the forecast period. For instance, in April 2020, American Well launched Amwell Private Practice that is a secure, simple and cost-effective solution for doctors to deliver virtual primary or specialty care for COVID19 patients. There has been a significant rise in telemental health visits over the past decade in the U.S. and the trend is expected to continue during the forecast period, thereby contributing to the adoption of telemedicine systems by hospitals and healthcare settings.

Grand View Research has segmented the global telemedicine market by component, technology, application, delivery mode, type, end-use, and region:

• Telemedicine Component Outlook (Revenue, USD Million, 2016 – 2028)
  • Product
    • Hardware
    • Software
    • Others
  • Services
    • Tele-consulting
    • Tele-monitoring
    • Tele-education
• Telemedicine Technology Outlook (Revenue, USD Million, 2016 – 2028)
  • Store and forward
  • Real time
  • Others
• Telemedicine Application Outlook (Revenue, USD Million, 2016 – 2028)
  • Teleradiology
  • Telepsychiatry
  • Telepathology
  • Teledermatology
  • Telecardiolog
  • Others
• Telemedicine Delivery Mode Outlook (Revenue, USD Million, 2016 – 2028)
  • Web/Mobile
    • Telephonic
    • Visualized
  • Call Centers
• Telemedicine Type Outlook (Revenue, USD Million, 2016 – 2028)
  • Tele-hospital
  • Tele-home
• Telemedicine End-use Outlook (Revenue, USD Million, 2016 – 2028)
  • Providers
  • Payers
  • Patients
  • Other End Users
• Telemedicine Regional Outlook (Revenue, USD Million, 2016 – 2028)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
    • Switzerland
    • Sweden
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Singapore
    • Malaysia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players of Telemedicine Market

• MDlive Inc.
• SteadyMD Inc.
• Maven, Inc.
• iCliniq
• HealthTap, Inc.
• BioTelemetry, Inc.
• American Well
• CVS Health
• Synapse Medicine
• Practo
• Teladoc Health, Inc.
• Doctor On Demand, Inc.
• AMD Global Telemedicine
• Aerotel Medical Systems (1998) Ltd.
• Plantronics, Inc. (Polycom)

Find more research reports on Healthcare IT Industry, by Grand View Research:

• eHealth Market – The global eHealth market size was valued at USD 85.44 billion in 2014 and is expected to increase at the rate of 15.8% over the forecast period.
• U.S. Telehealth Market – The U.S. telehealth market size was valued at USD 572.0 million in 2014. Key drivers of the market include rising demand for centralization of healthcare administration and enhanced quality and safety of the applications.
• Telepsychiatry Market – The global telepsychiatry market size was valued at USD 5.5 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 24.7% from 2020 to 2027.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: https://www.grandviewresearch.com 
Follow Us: LinkedIn | Twitter 

SOURCE Grand View Research, Inc.

The post Telemedicine Market Size Worth $298.9 Billion By 2028 | CAGR: 22.4%: Grand View Research, Inc. appeared first on Medika Life.

Date of Release: February 23, 2021

Doha, Qatar: A group of researchers at Qatar Foundation have reported the first and largest genetic association study in the Middle East, that has been published online in  Nature Communications – a leading a peer-reviewed, open access, scientific journal published by Nature Research.

The study titled “Whole genome sequencing in the Middle Eastern Qatari population identifies genetic associations with 45 clinically relevant traits” highlights a vital piece of information wherein now there is a better understanding of the genetic risk factors that are specific to the Arab population, including those that are shared with other ethnicities.

Qatar was among the first countries to launch its own large-scale, national genome project. Qatar Genome combines whole genome sequencing data with comprehensive phenotypic resource collected at Qatar Biobank, and is considered the first, largest and most ambitious population-based projects of its kind in the Middle East.

This kind of studies can be considered as experiments conducted by nature, where the natural variation found in the genomes of thousands of Qataris is linked to variations in their respective blood tests. The results from this project are shared publicly, ensuring that the specificities of the Arab genomes will be taken into consideration in future research on new treatments and therapies..

The study – led by researchers at Qatar Foundation’s (QF’s) Hamad Bin Khalifa University (HBKU) and QF’s partner university Weill Cornell Medicine – Qatar (WCM-Q), along with other scientists from the Qatar Genome Research Consortium – includes over 6,000 Qatari individuals with whole genome sequence data.

By performing detailed assessments of genetic variants across the whole genome in 6,218 individuals, comprising data from 45 clinically relevant traits, this study identified about 300 independent genetic signals. Some of these signals were predominantly found in the Qatari population. This observation was then confirmed in a further 7,768 subjects from QF’s Qatar Biobank.

Omar Albagha, Principal Investigator from HBKU’s College of Health and Life Sciences, says: “The study provides new insights into the genetic architecture of clinical laboratory tests and identifies for the first time genetic variations that are specific to the population of Qatar. The study also shows that findings from genetic studies in European populations don’t translate well when applied to our population in the Middle East. This argues for further studies to define the genetic architecture of diseases in our region. We are excited because the study represents a foundation for the implementation of precision medicine in the Middle East.”  

Karsten Suhre, Director of Bioinformatics Core at Weill Cornell Medicine – Qatar and joint senior author on the paper, says: “It has been a long but successful journey from the first patient recruitments to Qatar Biobank to analyzing the resulting enormous genetic data set for associations with clinically relevant traits, and we as a consortium are proud to contribute with this paper to the international effort of obtaining an even better understanding of our human genome.”

“Qatar Genome Research Consortium gave research groups the platform to study whole genome sequencing and other omics data to empower the genetic discoveries in this part of the world, which otherwise would be under-represented. said  Professor Said Ismail, Director of QF’s Qatar Genome, part of QF Research, Development, and Innovation.

Reference: 

Thareja G, Al-Sarraj Y, Belkadi A, Almotawa M, the Qatar Genome Program Research (QGPRC) Consortium, Suhre K, Albagha O.M.E. “Whole genome sequencing in the Middle Eastern Qatari population identifies genetic associations with 45 clinically relevant traits” Nature Communications 2021 https://doi.org/10.1038/s41467-021-21381-3 

About Qatar Genome Program

Qatar Genome Program (QGP) is the largest genome project in the Middle East with a mission to promote genomic research and clinical implementation at a national level. QGP is designed around a comprehensive strategy involving large scale genome sequencing and multi-omics data, establishing local and international research partnerships, building local human capacity, facilitating integration into the healthcare system, drafting guidelines and policies, raising public awareness as well as empowering and educating patients.

About Qatar Biobank

Qatar Biobank is a medical research center performing vital health research through its collection of samples and information on health and lifestyle of the Qatari population.

Qatar Biobank was created in collaboration with Hamad Medical Corporation and the Ministry of Public Health to enable local scientists to conduct medical research on prevalent health issues in Qatar.

Qatar Genome and Qatar Biobank are both Research, Development & Innovation entities within Qatar Foundation for Education, Science and Community Development.

About Hamad Bin Khalifa University

Innovating Today, Shaping Tomorrow

Hamad Bin Khalifa University (HBKU), a member of Qatar Foundation for Education, Science, and Community Development (QF), was founded in 2010 as a research-intensive university that acts as a catalyst for transformative change in Qatar and the region while having global impact. Located in Education City, HBKU is committed to building and cultivating human capacity through an enriching academic experience, innovative ecosystem, and unique partnerships. HBKU delivers multidisciplinary undergraduate and graduate programs through its colleges, and provides opportunities for research and scholarship through its institutes and centers. For more information about HBKU, visit www.hbku.edu.qa.

About Weill Cornell Medicine-Qatar

Weill Cornell Medicine – Qatar is a partnership between Cornell University and Qatar Foundation. It offers a comprehensive six-year medical program leading to the Cornell University M.D. degree with teaching by Cornell and Weill Cornell faculty and by physicians at Hamad Medical Corporation (HMC), Aspetar Orthopedic and Sports Medicine Hospital, the Primary Health Care Corporation, the Feto Maternal Center, and Sidra Medicine, who hold Weill Cornell appointments. Through its biomedical research program, WCM-Q is building a sustainable research community in Qatar while advancing basic science and clinical research. Through its medical college, WCM-Q seeks to provide the finest education possible for medical students, to improve health care both now and for future generations, and to provide high quality health care to the Qatari population.

Qatar Foundation – Unlocking Human Potential

Qatar Foundation for Education, Science and Community Development (QF) is a non-profit organization that supports Qatar on its journey to becoming a diversified and sustainable economy. QF strives to serve the people of Qatar and beyond by providing specialized programs across its innovation-focused ecosystem of education, research and development, and community development.

QF was founded in 1995 by His Highness Sheikh Hamad bin Khalifa Al Thani, the Father Amir, and Her Highness Sheikha Moza bint Nasser, who shared the vision to provide Qatar with quality education. Today, QF’s world-class education system offers lifelong learning opportunities to community members as young as six months through to doctoral level, enabling graduates to thrive in a global environment and contribute to the nation’s development.

QF is also creating a multidisciplinary innovation hub in Qatar, where homegrown researchers are working to address local and global challenges. By promoting a culture of lifelong learning and fostering social engagement through programs that embody Qatari culture, QF is committed to empowering the local community and contributing to a better world for all.

For a complete list of QF’s initiatives and projects, please visit: www.qf.org.qa 

For any media inquiries, please contact: pressoffice@qf.org.qa

The post Qatar Genome Research Consortium Reports First and Largest Comprehensive Genetic Association Study in Middle East appeared first on Medika Life.

DATE OF RELEASE: Aug 14, 2020

DUBLIN/PRNewswire/ — The “DTC (Direct to Consumer) DNA Test Kits Market – Growth, Trends, and Forecasts (2020-2025)” report has been added to ResearchAndMarkets.com’s offering.

The Global DTC DNA Test Kits Market is anticipated to grow with a CAGR of nearly 24% during the forecast period.

The major factors attributing to the growth of this market are increasing demand for paternity testing, rising prevalence of hereditary diseases, and rise in interest of consumers & physicians in DTC kits & consequent rise in sales of DNA test kits.

Furthermore, the growing number of laboratories researching the DNA kits for gynecological purposes is also a major factor that drives the market growth. For instance, the National Congenital Anomaly and Rare Disease Registration Service has stated that around 3 to 6% of babies worldwide are born with a congenital anomaly every year, this increases the need for the prenatal testing for anomalies. The difficulty in understanding the results of the kits and very less information about the companies selling the kits are restraining the growth of the market.

Furthermore the market is largely penetrating towards new research fields of medicine and healthcare as such the innovation of probes for preimplantation, prenatal, and postnatal genetic testing research drives the overall market growth.

Key Market Trends

Demand for Ancestry Testing is Expected to Increase During the Forecast Period

An ancestry test is a DTC DNA-based test that reads specific locations of a subject’s genome, to find or validate ancestral hereditary relationships or to evaluate the ethnic combination of an individual. The increasing number of people who are interested in knowing their ancestors and family tree increases the demand for DTC DNA test kits, especially in developing countries.

The increasing number of companies such as 23andMe are found to offer various DNA kits that are helpful in ancestry testing. Developed countries are also witnessing the high demand for such products as awareness about such technologies is higher.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall DTC DNA test kits market, throughout the forecast period. The growth is due to factors such as the growing prevalence of congenital anomalies and increasing government initiatives for genetic diagnosis. In the North America region, the United States holds the largest market share due to factors such as high disposable income, and easy acceptance of such kits in the country is expected to increase the demand in this region.

However, Asia Pacific is anticipated to be the fastest-growing market due to the increasing awareness programs and developments undertaken by government bodies to accelerate genetic research in Asian countries. The Asia Pacific will proliferate at a speedy rate due to rapid technological updation in the healthcare sector.

Competitive Landscape

The market studied is moderately competitive and consists of few major players. Growing biotech industry is augmenting the rise in new entrants in this market. It is belived that there will be penetration of the few small to mid sized compaies in this market.

Key Topics Covered

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Paternity Testing
4.2.2 Increasing Number of Hereditary Diseases
4.2.3 Rise in Interest of Consumers & Physicians in DTC Kits & Consequent Rise in Sales of DNA Test Kits
4.3 Market Restraints
4.3.1 Lack of Awareness and Proper Genetic Counselling
4.3.2 Regulatory Challenges Pertaining to the Use of DTC Genetic Tests
4.4 Porter’s Five Force Analysis

5 MARKET SEGMENTATION
5.1 By Sample Type
5.1.1 Saliva
5.1.2 Cheek Swab
5.2 By Application
5.2.1 Genetic Relatedness
5.2.2 Health & Fitness
5.2.3 Ancestry Testing
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle-East & Africa
5.3.5 South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Ancestry.com LLC
6.1.2 23andMe
6.1.3 MyHeritage Ltd.
6.1.4 Gene by Gene
6.1.5 Living DNA Ltd.
6.1.6 National Geographic Partners, LLC
6.1.7 Helix OpCo, LLC
6.1.8 Veritas
6.1.9 Futura Genetics
6.1.10 Illumina, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/4c1k1p

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

The post Direct to Consumer DNA Test Kits Industry Report 2020-2025 appeared first on Medika Life.

DATE OF RELEASE: Aug. 7, 2020

DUBLIN /PRNewswire/ — The “Respiratory Device Accessories (Anesthesia and Respiratory Devices) – Global Market Analysis and Forecast Model (COVID-19 market impact)” report has been added to ResearchAndMarkets.com’s offering..

This report is built to visualize quantitative market trends within Anesthesia and Respiratory Devices therapeutic area. The model discusses in detail the impact of COVID-19 on Respiratory Devices Accessories market for the year 2020 and beyond.

Respiratory Devices Accessories are commonly used in hospitals, home settings, and long-term care facilities. The devices are available from device manufacturers and third party suppliers. In addition to epidemiological considerations, technological advancement in these accessories drives the growth of the market. The lack of awareness of respiratory conditions leading to a large undiagnosed and untreated population is the major challenge in this market.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Respiratory Devices Accessories and evolving competitive landscape.

• Insightful review of the key industry trends.
• Annualized total Respiratory Devices Accessories market revenue by segment and market outlooks from 2015-2030.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights.

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition the publisher’s analysts provide unique country specific insights on the market.
• SWOT analysis for Respiratory Devices Accessories market.
• Competitive dynamics insights and trends provided for Respiratory Devices Accessories market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Ambu A/S, Draegerwerk AG & Co. KGaA, Teleflex Inc, Laerdal Medical AS, Fisher & Paykel Healthcare Corporation Limited, Intersurgical Ltd., Armstrong Medical Ltd and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Reasons to Buy

• Understand the impact of COVID-19 on Respiratory Devices Accessories market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Respiratory Devices Accessories market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Respiratory Devices Accessories market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Respiratory Devices Accessories market from 2015-2030.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

For more information about this report visit https://www.researchandmarkets.com/r/2hye7d

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

The post Impact of COVID-19 on the Respiratory Device Accessories Market appeared first on Medika Life.